Revolution Medicines, Inc. Warrant
General ticker "RVMDW" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $77.3M (TTM average)
Revolution Medicines, Inc. Warrant follows the US Stock Market performance with the rate: 55.9%.
Estimated limits based on current volatility of 5.7%: low 11.08$, high 12.42$
Factors to consider:
- Total employees count: 883 (+65.4%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Limited operating history, Clinical trial failure, Insufficient capital, Commercialization challenges, Regulatory and compliance
- Current price 830.4% above estimated high
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.37$, 1.27$]
- 2026-12-31 to 2027-12-31 estimated range: [0.20$, 0.74$]
Financial Metrics affecting the RVMDW estimates:
- Positive: with PPE of -0.2 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -519.94 <= 0.28
- Positive: Investing cash flow per share per price, % of 68.37 > -0.64
- Negative: negative Net income
- Negative: Shareholder equity ratio, % of 69.28 > 63.63
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: negative Industry operating cash flow (median)
- Negative: Interest expense per share per price, % of 14.03 > 3.34
- Negative: Industry earnings per price (median), % of -15.99 <= 0
Short-term RVMDW quotes
Long-term RVMDW plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $11.58MM | $0.00MM | $0.00MM |
| Operating Expenses | $498.76MM | $689.52MM | $1,182.37MM |
| Operating Income | $-487.19MM | $-689.52MM | $-1,182.37MM |
| Non-Operating Income | $47.29MM | $88.68MM | $51.07MM |
| Interest Expense | $0.00MM | $0.00MM | $24.23MM |
| R&D Expense | $423.14MM | $592.23MM | $987.33MM |
| Income(Loss) | $-439.89MM | $-600.85MM | $-1,131.30MM |
| Taxes | $-3.52MM | $-0.75MM | $0.00MM |
| Net Income(Loss)* | $-436.37MM | $-600.09MM | $-1,131.30MM |
| Stockholders Equity | $1,826.19MM | $2,265.20MM | $1,631.30MM |
| Assets | $2,061.70MM | $2,558.30MM | $2,354.51MM |
| Operating Cash Flow | $-350.57MM | $-557.44MM | $-897.74MM |
| Capital expenditure | $7.73MM | $10.31MM | $15.99MM |
| Investing Cash Flow | $-342.60MM | $-554.39MM | $118.06MM |
| Financing Cash Flow | $1,229.20MM | $959.41MM | $621.52MM |
| Earnings Per Share** | $-3.86 | $-3.58 | $-5.95 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.